

# Biosynthesis of silver nanoparticles using *Mitracarpus scaber* extracts for the treatment of infectious disease: synthesis, characterization, antibacterial and anti-inflammatory efficacy

Adesipe TI<sup>1, 2</sup>[ID](#), Adebayo AH<sup>1, 3</sup>[ID](#) Iweala EJ<sup>1, 4, 5</sup>[ID](#)

<sup>1</sup>Department of Biochemistry, College of Science and Technology, Covenant University, Ota, Ogun State, Nigeria

<sup>2</sup>Department of Science Laboratory Technology, Federal Polytechnic, Ilaro, Ogun state, Nigeria

<sup>3</sup>Office of the Vice Chancellor, Covenant University, Ota, Ogun State, Nigeria

<sup>4</sup>Covenant University Public Health and Wellbeing Research Cluster (CUPHWERC), Covenant University, Ota, Ogun State, Nigeria

<sup>5</sup>Covenant Applied Informatics and Communication African Centre of Excellence (CApIC-ACE), Covenant University, Ota, Ogun State, Nigeria

Submitted: 28<sup>th</sup> February 2024

Accepted: 8<sup>th</sup> June 2024

Published: 30<sup>th</sup> June 2024

[ID](#): Orcid ID

## Abstract

**Objective:** Due to the need for better treatments for infectious disorders, the antibacterial and anti-inflammatory potential of silver nanoparticles (AgNPs) of *Mitracarpus scaber* (*M.scaber*) extracts were assessed in this study.

**Methods:** AgNPs were synthesized from 0.1M AgNO<sub>3</sub> solution using *M.scaber* aqueous and ethanolic extracts as capping and reducing agents. FTIR, UV-VIS, FESEM and XRD studies were used to analyze the generated AgNPs. The Agar well diffusion method was used to evaluate their antibacterial activity against *E. coli*, while egg albumin and carrageenan-induced paw oedema assays were used to measure the anti-inflammatory activity of silver nanoparticles of aqueous and ethanol extracts of *M.scaber* (A.AgNPs and E.AgNPs).

**Result:** The formation of A.AgNPs and E.AgNPs at  $\lambda$  max = 425 nm and 410 nm, respectively, were demonstrated by UV-vis spectroscopy. The XRD pattern showed that the crystalline phase of silver and the generation of A.AgNPs and E.AgNPs were well aligned. Agglomerated A.AgNPs and E.AgNPs with particle sizes ranging from 5 to 20 nm were seen in the FESEM micrograph. The antibacterial activity result showed that, in a dose-dependent manner, A.AgNPs had a significantly ( $P < 0.05$ ) higher antibacterial activity against *E. coli* than E.AgNPs. The anti-inflammatory activity result showed that, following the fourth hour of the experimental setup, 100 mg/kg of A.AgNPs with peak effect (24.46 % inhibition) and 50 mg/kg of E.AgNPs with peak effect (18.11 % inhibition) produced the greatest inhibition of oedema development caused by carrageenan and egg albumin injection respectively.

**Conclusion:** The present work, therefore, concludes that A.AgNPs and E.AgNPs have potential value in the management of infectious diseases.

**Keywords:** Cystitis, Dysuria, Polypharmacy, Poly-pharmacology, Silver nanoparticles

## Plain English Summary

An emerging hallmark of drug development is the use of a single medication to treat several disease conditions. One basic mechanism of action is being deployed for the treatment of numerous conditions with a bid to provide better therapies and a more efficient research and development process. Silver

Correspondence:

Adesipe, Temitayo I

Department of Science Laboratory Technology,

Federal Polytechnic, Ilaro,

Ogun State, Nigeria.

+2347066025250, [lyanu.adesipe@federalpolytechnicilaro.edu.ng](mailto:lyanu.adesipe@federalpolytechnicilaro.edu.ng)

nanoparticles (AgNPs) are among the metallic nanoparticles that have been investigated the most because of their many commercial applications. It is worth noting that the size and shape of nanosilver influence their biomedical activities. Several studies have shown that plant extracts are utilized in the extracellular biosynthesis of silver nanoparticles, and that plant extract concentration as well as the type of plant extract (alcoholic or aqueous) used in this process can change the size and shape of the resulting nanoparticles. The present investigation assessed the potential antibacterial and anti-inflammatory properties of silver nanoparticles, which were biosynthesized using *M. scaber* aqueous and ethanol extracts, for the management of infectious diseases. The study's findings showed that silver nanoparticles made with *M. scaber* aqueous extract had stronger antibacterial and anti-inflammatory properties than those made with *M. scaber* ethanol extract due to their smaller size.

## Introduction

Antibiotics and anti-inflammatory drugs are the principal drugs used for the treatment of infectious diseases, especially infections of the respiratory tract, ENT, and urinary tract, however, inflammation does not necessarily imply infection (1). Nonetheless, in any infection, when pathogenic bacteria are present in the body, an inflammatory response always occurs. Common symptoms are swelling, heat, redness and pain in the inflamed organ to varying degrees. There are instances where the inflammatory reaction is so severe that it can be lethal and compromise the functionality of organ systems. For example, even though three days of antibiotic treatment is effective in 90% of cases of acute uncomplicated cystitis (AUC), a minor condition frequently brought on by *E. coli*, nonetheless, patients experience difficulty during therapy due to a variety of symptoms (2, 3). The predominant indication of cystitis is dysuria, which is typified by frequent, urgent, copious amounts of hematuria and lower abdomen pain in some cases (4). Due to these symptoms, 54% of women say that their quality of life has decreased and that they have difficulty with daily tasks or duties at work (5). Controlling dysuria is therefore beneficial for the treatment of cystitis. Since anti-inflammatory medications are anticipated to lessen dysuria, consequently improving life quality, they are frequently prescribed in addition to antibiotics to treat infectious disorders. This results in polypharmacy, which is the word for when a patient is prescribed two or more drugs concurrently (6). Since every medication has its side effects it poses to the body; for instance, common antibiotics such as Amoxil or Cefuroxime used for the management of *E.coli* infections as well as conventional anti-inflammatory medicines have been linked to hypersensitivity, gastrointestinal, neurological, renal, cardiac and hepatic adverse effects (7, 8, 9), polypharmacy is frequently linked to a lower quality of life, which includes diminished mobility and mental capacity (10). Polypharmacy is also not cost-efficient (11, 12). This has led to the repurposing of many already existing drugs (13). Drug repurposing takes advantage of the fact that a single molecule can affect several biological

targets. This is referred to as polypharmacology (14). Plants have been a major target for polypharmacology due to the wide variety of secondary metabolites contained in them, however, the use of herbal therapeutic molecules as drugs is difficult for a variety of reasons, including low plant yield, plant extracts' solubility in water and other solvents, the presence of cytotoxic components in the extract, the sample's limited bioavailability, and the improper use of readily available phytomedicines which can result in toxicity (15). The pharmacokinetics and efficacy of medicinal plants can thus be greatly enhanced if they are used to make nanoparticles (16). Amidst numerous available metal nanoparticles, silver nanoparticles have been acknowledged all over the world since they are very effective, less harmful, and best suited for medical uses (17). Silver nanoparticles are commonly made via chemical and physical techniques that require the use of harmful elements as reducing agents; nevertheless, the employment of these agents has resulted in several biological issues due to their overall toxicity (18). The biosynthesis of silver nanoparticles (AgNPs) utilizing medicinal plants is therefore a notable approach for several therapeutic improvements and efficient drug delivery (19).

Several researchers have studied the antimicrobial and anti-inflammatory properties of biosynthesized silver nanoparticles separately based on their interests. For example, the antimicrobial property of silver nanoparticles biosynthesized using *Cymbopogon citratus* leaf extract and *Carduus crispus* was studied alone by Rakib-Uz-Zaman et al., (20) and Urnukhsaikhan et al., (21) respectively while Xu et al., (22) and Khashan et al., (23) evaluated only the anti-inflammatory property of silver nanoparticles synthesized using aqueous extracts of *Ageratum conyzoides* and aqueous curcumin extract respectively. However, a growing amount of research has indicated that anti-inflammatory medications may have some antimicrobial and anti-biofilm effects on clinically significant microorganisms and vice versa (24, 25, 26). More so, silver nanoparticles have been noted to have the ability to directly combat

pathogens as well as associated inflammatory processes (27). This ability is due to their remarkable surface-to-volume ratio and enhanced bioavailability towards cells and tissues (28). Therefore, in a bid to find agents that can resolve infectious diseases in a way that is modulatory, efficient, and well-tolerated by the body, this investigation assessed the antibacterial and anti-inflammatory properties of silver nanoparticles that were biosynthesized using *Mitracarpus scaber* aqueous and ethanol extract.

### Materials and Methods

*Mitracarpus scaber* (whole) plant was collected from the Federal Polytechnic Ilero school field in Ogun State, Nigeria, and verified by Dr Nodza George, a botanist at the University of Lagos' Department of Botany and Microbiology. Every reagent utilized in this investigation was of analytical grade.

#### *Preparation and extraction of the study plant material*

For four weeks, the entire *Mitracarpus scaber* plant was air-dried at ambient temperature (25.00 ± 2.00 °C). Following drying, the *M. scaber* samples were carefully stored in sealed bottles for later use after being finely ground in a household blender. The milled plant (1 kg each) was then extracted by maceration in 7 Ltrs of distilled water and ethanol respectively for 72 days. Next, filtration was performed using cheesecloth and the filtrate was dried at 50 °C using a low-pressure rotary evaporator (29). Dried samples were stored for further studies.

#### *Preliminary phytochemical analysis*

The presence of active components was checked in the aqueous and ethanol extracts of the *Mitracarpus scaber* plant using conventional procedures (30).

#### *Biosynthesis of silver nanoparticles*

Silver nitrate (AgNO<sub>3</sub>, 0.1 M) was prepared. After which 90 ml of the AgNO<sub>3</sub> solution was added into two separate flasks containing aqueous and ethanol extracts of *Mitracarpus scaber* (10 ml each). Both flasks were then allowed to stir continuously at 25 °C in a shaker for 24 hours. The resultant AgNPs were subsequently centrifuged for 20 minutes at 6000 rpm. The pellets were centrifuged and then repeatedly washed with distilled water to remove any remaining silver ion residues not converted and other unwanted impurities. The resulting AgNPs pellet was labelled as A.AgNPs for the aqueous extract and E.AgNPs for the ethanol extract. They were then stored for further characterization and analysis (31).

#### *Characterization of biosynthesized silver nanoparticles*

The generated silver nanoparticles were characterized using FESEM, FTIR, XRD and ultraviolet-visible spectroscopy (32). The reduction of pure Ag<sup>+</sup> to AgNPs was tracked by monitoring the UV spectrum of the reaction media of silver nitrate solution and aqueous or ethanol extract of *M. scaber* with a UV-Vis spectrophotometer. FTIR was employed to identify potential functional groups involved in the production of silver nanoparticles. FESEM was used to determine the size and morphology of the biosynthesized silver nanoparticles while XRD was used to determine their crystalline structure and composition.

#### *Estimation of total flavonoid and phenol contents of biosynthesized silver nanoparticles*

The quantity of flavonoids was measured using the colourimetric technique with aluminium chloride while the Follins method was used to determine the phenol content as described by Elamawi et al., (33). To express the flavonoid and phenol contents in the samples, the rutin gallic acid concentration equivalents (mg/100 g of extracted component) were utilized.

#### *In vitro antibacterial assay*

The assay organism; *Escherichia coli* (NCTC 10418) was provided by the University of Lagos Microbiology Laboratory from their stock culture. It was then isolated on selective and diagnostic media, to suppress additional contaminants.

#### *Sample preparation for antibacterial assay*

Three working samples each of silver nanoparticles biosynthesized using aqueous and ethanol extracts of *M. scaber* (A.AgNPs and E.AgNPs), 25 mg/ml, 50 mg/ml and 100 mg/ml were achieved by weighing 1 g of either A.AgNPs or E.AgNPs dissolved in 10 ml of sterile distilled water which was then used as diluent for double diluting to obtain other working concentrations.

#### *Screening of antibacterial activity*

The antibacterial characteristics of the test substances (aqueous and ethanolic crude extracts of *Mitracarpus scaber*) and biosynthesized silver nanoparticles (A.AgNPs and E.AgNPs) were evaluated using Agar well diffusion, following the methodology outlined by Sohail et al. (34). In a nutshell, standardized test organisms (1 ml) were seeded one at a time onto warm agar, and before plating, the mixture was well mixed using the roll-palm method. A cork borer was used to bore 10 mm-diameter wells in the nutritional agar plates after they had been set. Different concentrations of levofloxacin (standard

antibiotics), aqueous, ethanol extract of *Mitracarpus scaber*, and corresponding nanoparticles (A.AgNPs and E.AgNPs) were separately dispensed into the wells before incubation. Diffusion was allowed to occur for four hours. Following a 24-hour incubation period at 37 °C, the plates were checked for zones of inhibition.

#### Evaluation of anti-inflammation property

Egg albumin and carrageenan-induced paw oedema

The method of Azim et al., (35) was employed for the determination of anti-inflammatory

properties. In brief, forty-eight (48) adult albino mice (20–30 g) were randomly assigned to eight groups for each analysis after being refused food for a full day. Egg albumin or carrageenan suspension (0.1 ml each) was injected into the sub-plantar tissue of the right hind paw of mice to create inflammatory responses one hour after administration of test samples. Subsequently, at 0, 1, 2, 3, and 4 hours, the diameter of inflammation was measured with a vernier caliper. % inhibition of carrageenan-induced paw oedema model in rats by the test samples was then calculated using the formula;

$$\frac{\text{mean paw volume (control group)} - \text{Mean paw volume (treated group)}}{\text{Mean paw volume (control group)}}$$

**Table 1: Experimental design**

Groups	Carrageenan-Induced Oedema	Number of Mice	Egg Albumin-Induced Oedema	Number of Mice
1	Carrageenaan + Distilled water	3	Egg Albumin + Distilled water	3
2	Carrageenaan + A.AgNPs (50 mg/kg)	3	Egg Albumin + A.AgNPs(50 mg/kg)	3
3	Carrageenaan + A.AgNPs (100 mg/kg)	3	Egg Albumin + A.AgNPs(100 mg/kg)	3
4	Carrageenaan + A.AgNPs (200 mg/kg)	3	Egg Albumin + A.AgNPs(200 mg/kg)	3
5	Carrageenaan + E.AgNPs (50 mg/kg)	3	Egg Albumin + E.AgNPs(50 mg/kg)	3
6	Carrageenaan + E.AgNPs (100 mg/kg)	3	Egg Albumin + E.AgNPs(100 mg/kg)	3
7	Carrageenaan + E.AgNPs (200 mg/kg)	3	Egg Albumin + E.AgNPs(200 mg/kg)	3
8	Carrageenaan+Diclofenac (50 mg/kg)	3	Egg Albumin + Diclofenac (10 mg/kg)	3

#### Statistical analysis

Mean ± standard error of the mean (SEM) was used to depict all the data. The Data were analysed using Graph Pad, Prism 6, IL, USA). The statistics carried out included an analysis of variance (ANOVA). A multiple-range test was employed to ascertain a significant difference, defined at p<0.05.

#### Result

##### Qualitative phytochemical screening

The result of the qualitative phytochemical screening of the aqueous and ethanol extracts of *Mitracarpus scaber* is presented in Table 2 below.

**Table 2: Qualitative phytochemical screening of aqueous and ethanol extracts of *Mitracarpus scaber***

Phytocompound	Aqueous Extract	Ethanol Extract
Alkaloids	+	+
Saponins	+	+
Tannins	+	+
Flavonoids	+	+
C.glicosides	+	-
Steroids	+	+
Terpenoids	+	+
Anthraquinones	-	-
Reducing Sugars	+	+
Phlobatanins	-	-

Note: + =present, - =Not present

#### Synthesis and characterization of silver nanoparticles


UV-Visible spectroscopy

After twenty-four hours, it was confirmed by UV-

visible spectroscopy that the Ag ions in the solution mixtures had reduced to A.AgNPs and E.AgNPs, respectively (Figure 1). The spectra consisted of absorption peaks in the visible

region of the electromagnetic spectrum. Absorption peaks of 425 nm and 410 nm were observed for A.AgNPs and E.AgNPs


respectively, both of which were characteristic of silver nanoparticles.



**Figure 1: UV-VIS absorbance spectra of the colloidal silver nanoparticles prepared using aqueous and ethanol extract of *M.scaber* at 24hrs**

FTIR spectroscopy  
Possible biomolecules contained in aqueous and ethanol extracts of *Mitracarpus scaber* responsible for the synthesis and capping of


A.AgNPs and E.AgNPs respectively were determined by FTIR spectroscopy analysis. The analysis's outcome is shown in Figure 2 below.



**Figure 2: FTIR spectra of (a) biosynthesized A.AgNPs and (b) biosynthesized E.AgNPs**

XRD analysis  
The XRD patterns of the A.AgNPs and E.AgNPs synthesized are shown in Figure 3 below. The  $2\theta$  peaks observed at  $\sim 38.12^\circ$ ,  $\sim 44.30^\circ$ ,  $\sim 64.45^\circ$  and  $77.40^\circ$  for both biosynthesized silver

nanoparticles (A.AgNPs and E.AgNPs) correspond to (1 1 1), (2 0 0), (2 2 0) and (3 1 1) reflection planes of a fcc lattice of silver (ICSD No. 04-003-2941 and ICDD:04-006-2775 respectively).



**Figure 3: XRD pattern of A.AgNPs and E.AgNPs**

FESEM



The size and structure of the final biosynthesized nanoparticles (A.AgNPs and E.AgNPs) are revealed in Figure 4 below.




Figure 4: FESEM images of A (A.AgNPs) and B (E.AgNPs)

**Determination of total phenol and flavonoid content**

Table 3 below displays the results of the total flavonoid and phenol contents of the biosynthesized silver nanoparticles (A.AgNPs and E.AgNPs). The outcome showed that the total flavonoid content of the silver nanoparticles made using the aqueous extract of *Mitracarpus*

*scaber* was higher than that of the silver nanoparticles made with the ethanol extract of *Mitracarpus scaber* ( $p < 0.05$ ), however, the phenol concentrations of the silver nanoparticles made using the ethanol extract of *Mitracarpus scaber* were significantly ( $p < 0.05$ ) higher than those made with the aqueous extract of the same plant.

**Table 3: Total phenol and flavonoid contents of biosynthesized silver nanoparticles (A.AgNPs and E.AgNPs)**

	Total Phenol (mg/100g)	Total Flavonoid (mg/100g)
A.AgNPs	139.11 ± 0.04	178.56± 0.18*
E.AgNPs	142.47± 0.02*	172.57 ± 0.02

**Determination of antibacterial activity**

Table 4 below lists the antibacterial activity of various concentrations of silver nanoparticles that were biosynthesized using *Mitracarpus scaber* aqueous and ethanol extracts against *E. coli*. The outcome showed that silver

nanoparticles made using *Mitracarpus scaber* aqueous extract exhibited more antibacterial activity than those made with *Mitracarpus scaber* ethanol extract ( $p < 0.05$ ). The antibacterial activity of both nanoparticles increased in a concentration-dependent manner.

**Table 4: Antibacterial activities (Zone of inhibition) of different concentrations of silver nanoparticles biosynthesized using aqueous and ethanol extracts of *Mitracarpus scaber* (A.AgNPs and E.AgNPs) against *E. coli***

Concentration	Sample	<i>E. coli</i>
25 (mg/ml)	A.AgNPs	1.75±0.01*
	E.AgNPs	1.50±0.01
50 (mg/ml)	A.AgNPs	1.95±0.01*
	E. AgNPs	1.73±0.01
100 (mg/ml)	A. AgNPs	2.33±0.01*
	E.AgNPs	1.93±0.01
6.25 (µg/ml) 12.5 (µg/ml) 25 (µg/ml) 50 (µg/ml)0	Levofloxacin	1.05±0.00
		1.10±0.00
		1.40±0.00
		1.60±0.00
		1.60±0.00

Values are mean ± SEM (n = 3)

*Anti-inflammatory activity of biosynthesized silver nanoparticles*

Carrageenan-induced oedema) in mice

inflammation (paw

The result of the anti-inflammatory activity of biosynthesized silver nanoparticles against carrageenan-induced inflammation (paw oedema) in mice is shown in Table 4 below. The greatest inhibition of oedema development with peak effect (24.46 % inhibition) was produced by

100 mg/kg of biosynthesized silver nanoparticles using an aqueous extract of *Mitracarpus scaber* at the fourth hour ( $p < 0.05$ ). This effect was comparable to that elicited by Diclofenac and 200 mg/kg of biosynthesized silver nanoparticles using an aqueous extract of *Mitracarpus scaber*.

**Table 4: Effect of different doses of biosynthesized silver nanoparticles (A.AgNPs and E.AgNPs) and Diclofenac on carrageenan-induced paw oedema in Mice**

	Carr Grp+ Dist Water	Carr+A.AgNPs (50 mg/kg)	Carr+A.AgNPs (100mg/kg)	Carr+A.Ag NPs (200 mg/kg)	Carr+E.AgNPs (50 mg/kg)	Carr+E.AgNPs (100 mg/kg)	Carr+E.AgNPs (200 mg/kg)	Carr+Diclo (50mg/kg)
0 hr	0.487±0.01	0.530±0.01	0.533±0.01	0.517±0.01	0.513±0.02	0.497±0.01	0.537±0.06	0.503±0.02
1 hr	0.973±0.08	0.903±0.01	0.803±0.02*	0.893±0.04	0.823±0.02*	0.7967±0.03*	0.827±0.09*	0.800±0.02*
2 hrs	1.030±0.07	1.007±0.05	0.870±0.03*	0.970±0.03	0.850±0.02*	0.903±0.01	0.860±0.03*	0.880±0.01*
3 hrs	1.163±0.11	0.940±0.04*	0.867±0.04*	0.897±0.02*	0.883±0.02*	0.9533±0.00*	0.917±0.03*	0.860±0.06*
4hrs	1.010±0.05	0.817±0.02 (19.11%) <sup>†</sup>	0.763±0.02 (24.46%) <sup>†</sup>	0.807±0.03 (20.10 %) <sup>†</sup>	0.817±0.03 (19.11%) <sup>†</sup>	0.837±0.01 (17.13%) <sup>†</sup>	0.830±0.03 (17.82%) <sup>†</sup>	0.803±0.07 (20.50%) <sup>†</sup>

Values are mean ± SEM (n = 3). \*P < 0.05, significant decrease in oedema development compared with control. % Inhibition is indicated by values in parenthesis

Egg albumin-induced inflammation (paw oedema) in mice

The result of the anti-inflammatory activity of biosynthesized silver nanoparticles against egg albumin-induced inflammation (paw oedema) in mice is shown in Table 5 below. The greatest inhibition of oedema development with peak

effect (18.11 % inhibition) was produced by 50 mg/kg of biosynthesized silver nanoparticles using ethanol extract of *Mitracarpus scaber* at the fourth hour (P < 0.05). This effect was comparable to that elicited by the other treatment groups as revealed below.

**Table 5: Effect of different doses of biosynthesized silver nanoparticles (A.AgNPs and E.AgNPs) and Diclofenac on Egg albumin-induced paw oedema in Mice**

	Egg Albumin +Dist.Water	Egg Albumin+A.A gNPs (50 mg/kg)	Egg Albumin+A.A gNPs (100 mg/kg)	Egg Albumin+A .AgNPs(200 mg/kg)	Egg Albumin+E.Ag NPs (50 mg/kg)	Egg Albumin+E.A gNPs (100 mg/kg)	Egg Albumin+E. AgNPs (200 mg/kg)	Egg Albumin+ Diclo (50 mg/kg)
0hr	1.143±0.04	1.253±0.02	1.177±0.00	1.210±0.03	1.287± 0.01	1.290± 0.01*	1.220±0.02	1.183±0.01
1 hr	1.907± 0.01	1.917±0.01	1.863±0.03	1.873±0.01	1.760±0.02*	1.883±0.03	1.743±0.10*	1.703±0.07*
2 hrs	2.193± 0.07	1.650±0.02*	1.997±0.04*	2.053±0.08	1.857±0.02*	1.903±0.06*	1.823±0.05*	1.830 ±0.04*
3 hrs	1.910± 0.06	1.543±0.03*	1.713±0.03*	1.930± 0.01	1.610±0.03*	1.713±0.04*	1.697±0.05*	1.760±0.02
4 hrs	1.933±0.06	1.700±0.02 (12.05 %) <sup>†</sup>	1.610±0.02 (16.71%) <sup>†</sup>	1.623±0.02 (16.03%) <sup>†</sup>	1.583±0.03 (18.11%) <sup>†</sup>	1.663±0.03 (13.97%) <sup>†</sup>	1.633±0.07 (15.52%) <sup>†</sup>	1.657±0.04 (14.28%) <sup>†</sup>

Values are mean ± SEM (n = 3). \*p < 0.05, a significant decrease in oedema development compared with control. % Inhibition is indicated by values in parenthesis

## Discussion

Qualitative phytochemical evaluations of the aqueous and ethanol extracts of *M. scaber* showed the presence of alkaloids, tannins, saponins, steroids, flavonoids, reducing sugars and terpenoids in both extracts while the aqueous extract had C.glycosides additionally present (Table 3). These phytochemical constituents have been reported for their medicinal properties (36, 37, 38). However, since the report has shown that biosynthesized silver nanoparticles possess enhanced pharmaceutical properties than crude extracts (39), silver nanoparticles were biosynthesized using aqueous and ethanol extracts of *M. scaber*.

In this study, the generation of metallic AgNPs was verified using the UV-Vis characteristic absorption band of silver nanoparticles, which has a wavelength between 300 and 800 nm. The

maximum absorbance peak of AgNPs of aqueous and ethanol extracts of *M. scaber* (Figure 1) was observed in the surface plasmon resonance region between 425 and 410 nm, respectively. Similar peaks were reported by Maheswari et al., (40) for biosynthesized silver nanoparticles using aqueous extracts of the leaf and bark of *Neolamarkia cadamba*. The existence of biomolecules including phenols, saponins, flavonoids, and terpenoids was confirmed by the functional groups shown by the FTIR spectrum (Figure 2), which suggests that these biomolecules served as capping and stabilizing agents for the synthesized nanoparticles. A similar finding has been reported in the literature (41). The crystalline character of the Ag nanoparticles produced by the extracts is amply demonstrated by the XRD measurements (Figure 3). The 2θ peaks

observed at  $\sim 38.12^\circ$ ,  $\sim 44.30^\circ$ ,  $\sim 64.45^\circ$  and  $77.40^\circ$  for both biosynthesized silver nanoparticles (A.AgNPs and E.AgNPs) correspond to (1 1 1), (2 0 0), (2 2 0) and (3 1 1) reflection planes of a fcc lattice of silver (ICSD No. 04-003-2941 and ICDD:04-006-2775 respectively). Similar XRD patterns of silver nanoparticles have been reported (42). Evident in the FESEM micrograph are agglomerated silver nanoparticles with particle sizes ranging from 5- 20 nm, with the silver nanoparticles biosynthesized using aqueous extract of *M. scaber* presenting the smallest particles (Figure 4). Silver nanoparticles with similar size ranges of 5-20 nm have been reported in the literature (43).

The result of the antibacterial activity revealed that A.AgNPs exhibited significant antibacterial activity against *E. coli* in a dose-dependent manner than E.AgNPs. This could be a result of the higher levels of flavonoids contained in A.AgNPs. Even though Stanković et al., (44) reported that there is little to no correlation between *Teucrium* species' antibacterial activity and their flavonoid content, Dzoyem et al., (45) reported that out of the eleven (11) compounds isolated from *Pseudarthria hookeri*, flavonoids from this plant showed the highest antibacterial activity against *E. coli*. The greater antibacterial activity of silver nanoparticles biosynthesized using aqueous extract of *M. scaber* against *E. coli* could also be a result of its smaller sizes in comparison to silver nanoparticles biosynthesized using ethanol extract of *M. scaber*. Several researchers have reported that the antibacterial activity of silver nanoparticles is greatly influenced by size and that the smaller the size of a nanoparticle, the greater the antibacterial activity it exhibits (46, 47). This is because compared to bigger size nanoparticles, the smaller size AgNPs aggregate more readily and affect the target organelle more (48). In all the antibacterial activity of A.AgNPs and E.AgNPs were greater than that exhibited by the different standard concentrations of Levofloxacin used against *E. coli*. This result is different from the findings of Sher et al., (49) who reported that Levofloxacin had a slightly higher antibacterial effect against *E. coli* than silver nanoparticles biosynthesized using *Hippeastrum hybridum* extract. This could be a result of differences in plant extracts and concentrations used for synthesis and the antibacterial assay.

Meanwhile, paw oedema in rats brought on by egg albumin or carrageenan is a well-known animal model used to assess how effective herbal remedies and prescription drugs are in reducing inflammation (50, 51). In the process of wanting to determine also the anti-inflammatory potential of the biosynthesized silver

nanoparticles, the biphasic phase of oedema formation was achieved by applying carrageenan and egg albumin to different groups of rat paws. For the carrageenan assay, rats in the control group developed oedema ( $1.163 \pm 0.11$  cm increase in paw circumference), which peaked three hours after injecting the phlogistic drug (carrageenan) into their right hind paw's subplantar tissue while for the egg albumin assay, rats in the control group developed oedema, which peaked two hours following subplantar injection of egg albumin into the right hind paw ( $2.193 \pm 0.07$  cm increase in paw circumference). These findings are consistent with earlier research that indicates the peak carrageenan and egg albumin effects occur 3 hours and 2 hours respectively after injection (52, 53). According to the literature, for one to one and a half hours, the first phase of oedema formation is characterized by non-phagocytic oedema which is followed by a second phase that lasts for two to four hours and has increased oedema production. Different mediators, such as histamine, serotonin, and bradykinin, operate on vascular permeability to initiate the initial phase of oedema, while overproduction of prostaglandins causes the late phase, or second phase (50).

The result of the anti-inflammatory activity of the synthesized silver nanoparticles (Table 4 and Table 5) revealed that the greatest inhibition of oedema development caused by carrageenan and egg albumin injection after the 4<sup>th</sup> hour of experimental set-up ( $P < 0.05$ ) was produced by 100 mg/kg of biosynthesized silver nanoparticles using aqueous extract of *Mitracarpus scaber* with peak effect (24.46 % inhibition) and 50 mg/kg of biosynthesized silver nanoparticles using ethanol extract of *Mitracarpus scaber* with peak effect (18.11 % inhibition) respectively. These effects were comparable to those elicited by Diclofenac for both assays. This implies that biosynthesized silver nanoparticles using aqueous and ethanol extracts of *M. scaber* have antagonistic reactions to all inflammation mediators implicated in the vascular and cellular phases. However, the anti-inflammatory activity observed in this study is lesser than the anti-inflammatory activity reported by Das, Mondal, Patowary and Malipeddi, (54) for AgNPs biosynthesized using aqueous leaf extract of *Ipomoea eriocarpa*.

## Conclusion

The outcome of the study showed that aqueous and ethanol extract of *M. scaber* can be utilised for the biosynthesis of silver nanoparticles. This is being reported for the first time. The result also demonstrated that silver nanoparticles biosynthesized using aqueous and ethanol extracts of *M. scaber* possessed significant



antibacterial and anti-inflammatory properties and could be utilized as an effective therapy in the management of infectious diseases especially those caused by *Escherichia coli* after proper pharmacological investigations.

#### List of Abbreviations

AgNPs:	Silver nanoparticles
A. AgNPs:	Silver nanoparticles biosynthesized using an aqueous extract of <i>Mitracarpus scaber</i>
AgNO <sub>3</sub> :	Silver nitrate
ANOVA:	Analysis of Variance
E.AgNPs:	Silver nanoparticles biosynthesized using ethanol extract of <i>Mitracarpus scaber</i>
<i>E. coli</i> :	<i>Escherichia coli</i>
ENT:	Ear, Nose and Throat Infection
FESEM:	Field emission scanning electron microscopy
FTIR:	Fourier-transform infrared spectroscopy
R and D:	Research and Development
<i>M. Scaber</i> :	<i>Mitracarpus scaber</i>
SEM:	Standard Error of Mean
UV-VIS:	Ultraviolet-visible spectroscopy
XRD:	X-ray diffraction analysis

#### Declarations

##### *Ethics approval and consent to participate*

This research protocol was approved by the Ethics Committee of Covenant University, Nigeria (CU/HREC/OES/096/21). The current regulations of the Animal Protection Act (Law 27,265) were adopted.

##### *Consent for Publication:*

All the authors gave their consent for the publication of the work under the Creative Commons Attribution Non-Commercial 4.0 license. Otherwise, all copyright ownership including all rights incidental thereto is conveyed to the journal when published.

##### *Availability of data and materials*

The study data is available upon request to the corresponding author.

##### *Competing interests*

There are no declared conflicts of interest involving the authors.

##### *Funding*

Not applicable

##### *Authors' contributions*

AAH came up with the concept under the guidance of AAH and IEJ, took care of the material preparation, data collecting, and analysis, and wrote the first draft of the manuscript. AAH and

IEJ then proofread it. Every author participated in the full process of revision.

#### Acknowledgements

Not applicable.

#### References

1. Kuchar E, Karlikowska-Skwarnik M, Wawrzuta D. Anti-inflammatory therapy of infections. Encyclopedia of Infection and Immunity. 2022 Apr 8; 791. <https://doi.org/10.1016/B978-0-12-818731-9.00181-6>.
2. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clinical infectious diseases. 2011 Mar 1; 52(5):e103-20. <https://doi.org/10.1093/cid/ciq257>.
3. Li R, Leslie SW. Cystitis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2023 May 30;1-54. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK482435/>.
4. Mehta P, Leslie SW, Reddivari AKR. Dysuria. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2023 Nov 12. PMID: 31751108.
5. Ko K, Lee WK, Oh CY, Lee SH, Cho ST, Bang WJ, Shin TY, Choo MS, Cho JS, Lee YG, Yang DY. Is a combination of antibiotics and non-steroidal anti-inflammatory drugs more beneficial than antibiotic monotherapy for the treatment of female acute uncomplicated cystitis? A randomized controlled pilot study. Urology Journal. 2018 Nov 17;15(6):365-9. <https://doi.org/10.22037/uj.v0i0.3716>.
6. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC geriatrics. 2017 Oct 10; 17:1-10. <https://doi.org/10.1186/s12877-017-0621-2>.
7. Akhavan BJ, Khanna NR, Vijhani P. Amoxicillin. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2023 Nov 17; 1-39. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK482250/>.
8. Omole AE, Awosika AO, Patel P. Cefuroxime. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2024 Jan 11; 1-44. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK599>

- 503/.
9. Klomjit N, Ungprasert P. Acute kidney injury associated with non-steroidal anti-inflammatory drugs. *European Journal of Internal Medicine*. 2022 Jul 1;101:21-8. <https://doi.org/8.10.1016/j.ejim.2022.05.003>
  10. Ponte ML, Wachs L, Wachs A, Serra HA. "Prescribing cascade. A proposed new way to evaluate it". *Medicina*. 2017 Feb 13; 77(1): 13–16. [PMID 28140305](https://pubmed.ncbi.nlm.nih.gov/28140305/).
  11. Bezerra HS, Costa AL, Pinto RS, de Resende PE, de Freitas GR. Economic impact of pharmaceutical services on polymedicated patients: A systematic review. *Research in Social and Administrative Pharmacy*. 2022 Sep 1; 18(9): 3492-500. <https://doi.org/10.1016/j.sapharm.2022.03.005>.
  12. Kwak MJ, Chang M, Chiadika S, Aguilar D, Avritscher E, Deshmukh A, Goyal P, Kim DH, Aparasu R, Holmes HM. Healthcare Expenditure Associated with Polypharmacy in Older Adults With Cardiovascular Diseases. *Am J Cardiol*. 2022 Apr 15;169:156-158. <https://doi.org/10.1016/j.amjcard.2022.01.012>.
  13. Pierzynowska K, Kamińska T, Węgrzyn G. One drug to treat many diseases: unlocking the economic trap of rare diseases. *Metabolic Brain Disease*. 2020 Sep 14;35(8):1237-40. <https://doi.org/10.1007/s11011-020-00617-z>.
  14. Hernández-Parra H, Cortés H, Avalos-Fuentes JA, Del Prado-Audelo M, Florán B, Leyva-Gómez G, Sharifi-Rad J, Cho WC. Repositioning of drugs for Parkinson's disease and pharmaceutical nanotechnology tools for their optimization. *Journal of Nanobiotechnology*. 2022 Sep 15;20(1):413. <https://doi.org/10.1186/s12951-022-01612-5>.
  15. Nasim N, Sandeep IS, Mohanty S. Plant-derived natural products for drug discovery: current approaches and prospects. *Nucleus (Calcutta)*. 2022 Oct 18;65(3):399-411. <https://doi.org/10.1007/s13237-022-00405-3>.
  16. Dewi MK, Chaerunisaa AY, Muhaimin M, Joni IM. Improved activity of herbal medicines through nanotechnology. *Nanomaterials*. 2022 Nov 18;12(22):4073. <https://doi.org/10.3390/nano12224073>.
  17. Khan MR, Urmi MA, Kamaraj C, Malafaia G, Ragavendran C, Rahman MM. Green synthesis of silver nanoparticles with its bioactivity, toxicity and environmental applications: A comprehensive literature review. *Environmental Nanotechnology, Monitoring and Management*. 2023 Aug 20; <https://doi.org/10.1016/j.enmm.2023.100872>.
  18. Dhaka A, Mali SC, Sharma S, Trivedi R. A review on biological synthesis of silver nanoparticles and their potential applications. *Results in Chemistry*. 2023 Sep 11; 101108. <https://doi.org/10.1016/j.rechem.2023.101108>.
  19. Habeeb Rahuman HB, Dhandapani R, Narayanan S, Palanivel V, Paramasivam R, Subbarayalu R, Thangavelu S, Muthupandian S. Medicinal plants mediated the green synthesis of silver nanoparticles and their biomedical applications. *IET nanobiotechnology*. 2022 Apr 15 ;16(4):115-44. <https://doi.org/10.1049/nbt2.12078>.
  20. Rakib-Uz-Zaman SM, Hoque Apu E, Muntasir MN, Mowna SA, Khanom MG, Jahan SS, Akter N, R. Khan MA, Shuborna NS, Shams SM, Khan K. Biosynthesis of silver nanoparticles from *Cymbopogon citratus* leaf extract and evaluation of their antimicrobial properties. *Challenges*. 2022 May 5; 13(1): 18. <https://doi.org/10.3390/challe13010018>.
  21. Urnuksaikhani E, Bold BE, Gunbileg A, Sukhbaatar N, Mishig-Ochir T. Antibacterial activity and characteristics of silver nanoparticles biosynthesized from *Carduus crispus*. *Scientific Reports*. 2021 Oct 26;11(1):21047. <https://doi.org/10.1038/s41598-021-00520-2>.
  22. Xu Z, Zha X, Ji R, Zhao H, Zhou S. Green Biosynthesis of Silver Nanoparticles Using Aqueous Extracts of *Ageratum Conyzoides* and Their Anti-Inflammatory Effects. *ACS Applied Materials and Interfaces*. 2023 Mar 7;15(11):13983-92. <https://doi.org/10.1021/acsami.2c22114>.
  23. Khashan AA, Dawood Y, Khalaf YH. Green chemistry and anti-inflammatory activity of silver nanoparticles using an aqueous curcumin extract. *Results in Chemistry*. 2023 Jan 1;5:100913. <https://doi.org/10.1016/j.rechem.2023.100913>.
  24. Leão C, Borges A, Simões M. NSAIDs as a drug repurposing strategy for biofilm control. *Antibiotics*. 2020 Sep 10; 9(9): 591. <http://dx.doi.org/10.3390/antibiotics9090591>.
  25. Paes Leme RC, da Silva RB. Antimicrobial Activity of Non-steroidal Anti-inflammatory Drugs on Biofilm: Current Evidence and Potential for Drug Repurposing. *Front Microbiol*. 2021 Jul 27;12:707629. <https://doi.org/10.3389/fmicb.2021.707629>.
  26. Tabatabaeifar F, Isaei E, Kalantar-

- Neyestanaki D, Morones-Ramírez JR. Antimicrobial and Antibiofilm Effects of Combinatorial Treatment Formulations of Anti-Inflammatory Drugs—Common Antibiotics against Pathogenic Bacteria. *Pharmaceutics*. 2022 Dec 20; 15(1): 4. <http://dx.doi.org/10.3390/pharmaceutics15010004>.
27. Huang Y, Guo X, Wu Y, Chen X, Feng L, Xie N, Shen G. Nanotechnology's frontier in combatting infectious and inflammatory diseases: prevention and treatment. *Signal Transduction and Targeted Therapy*. 2024 Feb 21;9(1):34. <https://doi.org/10.1038/s41392-024-01745-z>.
  28. Altammar KA. A review on nanoparticles: characteristics, synthesis, applications, and challenges. *Front Microbiol*. 2023 Apr 17; 14: 1155622. <https://doi.org/10.3389/fmicb.2023.1155622>.
  29. Ogunlana OO, Adetuyi BO, Rotimi M, Esalomi L, Adeyemi A, Akinyele J, Ogunlana OE, Adetuyi OA, Adebisi OA, Opata EK, Baty RS. Hypoglycemic and antioxidative activities of ethanol seed extract of *Hunteria umbellata* (Hallier F.) on streptozotocin-induced diabetic rats. *Clinical Phytoscience*. 2021 Jun 15;7(1):55. <https://doi.org/10.1186/s40816-021-00285-1>.
  30. Adewolu A, Adenekan AS, Uzamat OF, Ajayi OO. Ameliorative Effects of Ethanolic Leaf Extract of *Physalis angulata* (Ewe Koropo) on Diabetic-Induced Wistar Rats in South West Nigeria. *Open Journal of Medicinal Chemistry*. 2021 Nov 29 ;11(8): 594. ISSN: 2161-0444. <https://doi.org/10.1007/s12668-019-00691-3>.
  31. Krishnasamy Sekar R, Sridhar A, Perumalsamy B, Manikandan DB, Ramasamy T. In vitro antioxidant, antipathogenicity and cytotoxicity effect of silver nanoparticles fabricated by onion (*Allium cepa* L.) peel extract. *BioNanoScience*. 2020 Nov 22;10:235-48. <https://doi.org/10.1007/s12668-019-00691-3>.
  32. Elamawi RM, Al-Harbi RE, Hendi AA. Biosynthesis and characterization of silver nanoparticles using *Trichoderma longibrachiatum* and their effect on phytopathogenic fungi. *Egyptian Journal of Biological Pest Control*. 2018 Mar 8;28(1):1. <https://doi.org/10.1186/s41938-018-0028-1>.
  33. Aryal S, Baniya MK, Danekhu K, Kunwar P, Gurung R, Koirala N. Total Phenolic Content, Flavonoid Content and Antioxidant Potential of Wild Vegetables from Western Nepal. *Plants (Basel)*. 2019 Apr 11;8(4):96. <https://doi.org/10.3390/plants8040096>.
  34. Simon S, Sibuyi NR, Fadaka AO, Meyer M, Madiehe AM, du Preez MG. The antimicrobial activity of biogenic silver nanoparticles synthesized from extracts of Red and Green European pear cultivars. *Artificial Cells, Nanomedicine, and Biotechnology*. 2021 Jan 1;49(1):613-24. <https://doi.org/10.1080/21691401.2021.1980884>.
  35. Azim T, Wasim M, Akhtar MS, Akram I. An in vivo evaluation of anti-inflammatory, analgesic and antipyretic activities of newly synthesized 1, 2, 4 Triazole derivatives. *BMC Complement Med Ther*. 2021 Dec 31;21(1):304. <https://doi.org/10.1186/s12906-021-03485-x>.
  36. Liaqat N, Jahan N, Khalil-Ur-Rahman, Anwar T, Qureshi H. Green synthesized silver nanoparticles: Optimization, characterization, antimicrobial activity, and cytotoxicity study by hemolysis assay. *Front Chem*. 2022 Aug 29;10:952006. <https://doi.org/10.3389/fchem.2022.952006>.
  37. Habeeb Rahuman HB, Dhandapani R, Narayanan S, Palanivel V, Paramasivam R, Subbarayalu R, Thangavelu S, Muthupandian S. Medicinal plants mediated the green synthesis of silver nanoparticles and their biomedical applications. *IET nanobiotechnology*. 2022 Jun;16(4):115-44. <https://doi.org/10.1049/nbt.12078>.
  38. Zuhrotun A, Oktaviani DJ, Hasanah AN. Biosynthesis of Gold and Silver Nanoparticles Using Phytochemical Compounds. *Molecules*. 2023 Apr 5;28(7):3240. <https://doi.org/10.3390/molecules28073240>.
  39. Kumkoon T, Srisaisap M, Boonserm P. Biosynthesized Silver Nanoparticles Using *Morus alba* (White Mulberry) Leaf Extract as Potential Antibacterial and Anticancer Agents. *Molecules*. 2023 Jan 26;28(3):1213. <https://doi.org/10.3390/molecules28031213>.
  40. Maheswari J, Anjum MR, Sankari M, Narasimha G, Krishna SBN, Kishori B. Green synthesis, characterization and biological activities of silver nanoparticles synthesized from *Neolamarkia cadamba*. *ADMET DMPK*. 2023 Jul 1;11(4):573-585. <https://doi.org/10.5599/admet.1793>.
  41. Dada AO, Adekola FA, Dada FE, Adelani-Akande AT, Bello MO, Okonkwo CR, Inyinbor AA, Oluyori AP, Olayanju A, Ajanaku KO, Adetunji CO. Silver nanoparticle synthesis by *Acalypha wilkesiana* extract: phytochemical screening, characterization, influence of operational parameters, and preliminary antibacterial testing. *Heliyon*. 2019 Oct 2;5(10):e02517.

- <https://doi.org/10.1016/j.heliyon.2019.e02517>.
42. Rautela A, Rani J. Green synthesis of silver nanoparticles from *Tectona grandis* seeds extract: characterization and mechanism of antimicrobial action on different microorganisms. *Journal of Analytical Science and Technology*. 2019 Jan 22;10(1):1-0.<https://doi.org/10.1186/s40543-018-0163-z>.
  43. Ali M, Kim B, Belfield KD, Norman D, Brennan M, Ali GS. Green synthesis and characterization of silver nanoparticles using *Artemisia absinthium* aqueous extract—A comprehensive study. *Materials Science and Engineering: C*. 2016 Jan 1;58:359-65.<https://doi.org/10.1016/j.msec.2015.08.045>.
  44. Stanković MS, Stefanović O, Čomić L, Topuzović M, Radojević I, Solujić S. Antimicrobial activity, total phenolic content and flavonoid concentrations of *Teucrium* species. *Central European Journal of Biology*. 2012 Jun 6;7:664-71.<https://doi.org/10.2478/s11535-012-0048-x>.
  45. Dzoyem JP, Tchamgoue J, Tchouankeu JC, Kouam SF, Choudhary MI, Bakowsky U. Antibacterial activity and cytotoxicity of flavonoids compounds isolated from *Pseudarthria hookeri* Wight and Arn. (Fabaceae) S. Afr. J. Bot. Nov 3 2018;114:100–103.<https://doi.org/10.1016/j.sajb.2017.11.001>.
  46. Urnukhsaikhan E, Bold BE, Gunbileg A, Sukhbaatar N, Mishig-Ochir T. Antibacterial activity and characteristics of silver nanoparticles biosynthesized from *Carduus crispus*. *Sci Rep*. 2021 Oct 26;11(1):21047.<https://doi.org/10.1038/s41598-021-00520-2>.
  47. Wasilewska A, Klekotka U, Zambrzycka M, Zambrowski G, Świącicka I, Kalska-Szostko B. Physico-chemical properties and antimicrobial activity of silver nanoparticles fabricated by green synthesis. *Food Chem*. 2023 Jan 30; 400:133960.<https://doi.org/10.1016/j.foodchem.2022.133960>.
  48. Osonga FJ, Akgul A, Yazgan I, Akgul A, Eshun GB, Sakhaee L, Sadik OA. Size and Shape-Dependent Antimicrobial Activities of Silver and Gold Nanoparticles: A Model Study as Potential Fungicides. *Molecules*. 2020 Jun 9;25(11):2682.<https://doi.org/10.3390/molecules25112682>.
  49. Sher N, Alkhalifah DHM, Ahmed M, Mushtaq N, Shah F, Fozia F, Khan RA, Hozzein WN, Aboul-Soud MAM. Comparative Study of Antimicrobial Activity of Silver, Gold, and Silver/Gold Bimetallic Nanoparticles Synthesized by Green Approach. *Molecules*. 2022 Nov 15;27(22):7895.<https://doi.org/10.3390/molecules27227895>.
  50. Fatima H, Shahid M, Jamil A, Naveed M. Therapeutic Potential of Selected Medicinal Plants Against Carrageenan Induced Inflammation in Rats. *Dose Response*. 2021 Nov 27; 19(4) : 15593258211058028.<https://doi.org/10.1177/15593258211058028>.
  51. Hussain A, Aslam B, Muhammad F, Faisal MM. *In vitro* antioxidant activity and *in vivo* anti-inflammatory effect of *Ricinus communis* (L.) and *Withania somnifera* (L.) hydroalcoholic extracts in rats. *Brazilian Archives of Biology and Technology*. 2021 Nov 18;64: e21200783.<https://doi.org/10.1590/1678-4324-2021200783>.
  52. Belay R, Makonnen E. Evaluation of the anti-inflammatory activities of 70% ethanol leaves extract and solvent fractions of *Zehneria scabra* (L.f.) Sond (Cucurbitaceae) in rodents. *Biofarmasi J Nat Prod Biochem*. 2020 Feb 18; 1: 2580-42-56.<https://doi.org/10.13057/biofar/f180105>.
  53. Barung EN, Dumanauw JM, Duri MF, Kalonio DE. Egg white-induced inflammation models: A study of oedema profile and histological change of rat's paw. *J Adv Pharm Technol Res*. 2021 Apr 1; 12(2):109-112.[https://doi.org/10.4103/japtr.JAPTR\\_262\\_20](https://doi.org/10.4103/japtr.JAPTR_262_20).
  54. Das M, Mondal A, Patowary K, Malipeddi H. Biosynthesis of AgNPs using aqueous leaf extract of *Ipomoea eriocarpa* and their anti-inflammatory effect on carrageenan-induced paw oedema in male Wistar rats. *IET Nanobiotechnol*. 2017 Apr;11(3):225-229.<https://doi.org/10.1049/iet-nbt.2016.0034>.